본문바로가기

  • HOME
  • ABOUT
  • PIPELINE
  • INVESTOR
ENG
  • KOR
  • ENG

INVESTOR

  • News
  • PR
  • IR
Click to Subscribe
BBT News!
Click to Subscribe
BBT News!
  • Listing Eligibility Review for IPO on the KOSDAQ market has been cleared 2019-10-25 Read More
  • Bridge Biotherapeutics Presents Positive Results from Phase 1 Clinical Study of BBT-877 for Idiopathic Pulmonary Fibrosis (IPF) Treatments at the ERS International Congress 2019 2019-09-30 Read More
  • Boehringer Ingelheim Expands Idiopathic Pulmonary Fibrosis (IPF) Pipeline Through Collaboration and License Agreement with Bridge Biotherapeutics 2019-07-18 Read More
  • Bridge Biotherapeutics Joins JLABS @ Shanghai, China 2019-07-03 Read More
  • Bridge Biotherapeutics Announces Data Presentation from First-in-Human Study of BBT-877 for Idiopathic Pulmonary Fibrosis 2019-05-20 Read More
123

  • LEARN MORE ABOUT US
    페이스북 트위터 링크드인
  • CONTACT INFORMATION

    HQ: Suite 903-2, Bldg B, Innovalley, 253 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13486 Republic of Korea
    US Office: Bridge Biotherapeutics, Inc. in JLABS@TMC, 2450 Holcombe Blvd. Houston, TX 77021, USA

    Director, Jong-jin Lim (jong-jin.lim@bridgebiorx.com)
    Manager, Joengbin Ahn (Joengbin.ahn@bridgebiorx.com)

Copyrightⓒ 2018. Bridge Biotherapeutics, Inc. All rights reserved.